Literature DB >> 30507614

Immunotherapy transforms cancer treatment.

Neeha Zaidi, Elizabeth M Jaffee.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30507614      PMCID： PMC6307941          DOI： 10.1172/JCI126046

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   19.456


× No keyword cloud information.
  13 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

Authors:  F Stephen Hodi; Martin C Mihm; Robert J Soiffer; Frank G Haluska; Marcus Butler; Michael V Seiden; Thomas Davis; Rochele Henry-Spires; Suzanne MacRae; Ann Willman; Robert Padera; Michael T Jaklitsch; Sridhar Shankar; Teresa C Chen; Alan Korman; James P Allison; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

3.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

4.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

5.  A new member of the immunoglobulin superfamily--CTLA-4.

Authors:  J F Brunet; F Denizot; M F Luciani; M Roux-Dosseto; M Suzan; M G Mattei; P Golstein
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

6.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Authors:  Yoshiko Iwai; Masayoshi Ishida; Yoshimasa Tanaka; Taku Okazaki; Tasuku Honjo; Nagahiro Minato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

7.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

8.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

9.  Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.

Authors:  Heather L Kinkead; Alexander Hopkins; Eric Lutz; Annie A Wu; Mark Yarchoan; Kayla Cruz; Skylar Woolman; Teena Vithayathil; Laura H Glickman; Chudi O Ndubaku; Sarah M McWhirter; Thomas W Dubensky; Todd D Armstrong; Elizabeth M Jaffee; Neeha Zaidi
Journal:  JCI Insight       Date:  2018-10-18

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307
View more
  6 in total

1.  Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4+ effector T cell infiltration into murine pancreatic tumors.

Authors:  Neeha Zaidi; Sergio A Quezada; Janelle M Y Kuroiwa; Li Zhang; Elizabeth M Jaffee; Ralph M Steinman; Bei Wang
Journal:  Ann N Y Acad Sci       Date:  2019-04-04       Impact factor: 6.499

2.  Immune-related genes in tumor-specific CD4+ and CD8+ T cells in colon cancer.

Authors:  Xi Yang; Wei Wu; Yuefen Pan; Qing Zhou; Jiamin Xu; Shuwen Han
Journal:  BMC Cancer       Date:  2020-06-22       Impact factor: 4.430

3.  Characterization of the Immune Cell Infiltration Landscape in Esophageal Squamous Cell Carcinoma.

Authors:  Zhilin Sui; Xianxian Wu; Longde Du; Han Wang; Lijuan Yuan; Jian V Zhang; Zhentao Yu
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

Review 4.  Future Needs in Mast Cell Biology.

Authors:  Gilda Varricchi; Amato de Paulis; Gianni Marone; Stephen J Galli
Journal:  Int J Mol Sci       Date:  2019-09-06       Impact factor: 5.923

Review 5.  Moving Immune Therapy Forward Targeting TME.

Authors:  Kayla F Goliwas; Jessy S Deshane; Craig A Elmets; Mohammad Athar
Journal:  Physiol Rev       Date:  2020-08-13       Impact factor: 37.312

6.  Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development.

Authors:  Neeha Zaidi; Mariya Soban; Fangluo Chen; Heather Kinkead; Jocelyn Mathew; Mark Yarchoan; Todd D Armstrong; Shozeb Haider; Elizabeth M Jaffee
Journal:  JCI Insight       Date:  2020-09-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.